EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Does Next Generation Sequencing ( NGS )‐Based CYP2D6 Sequencing Improve Genotype–Phenotype Concordance in Tamoxifen‐Treated Patients?

Jeanne Petit iD, Julien Plenecassagnes, Aurelie Brice, Florence Dalenc, Ludovic Mallet, Etienne Chatelut iD, Ayman Al Saati, Fabienne Thomas iD

Clinical Pharmacology & Therapeutics · 2026-09 · 120 (3) · 731-744

DOI: 10.1002/cpt.70360 ↗

At a glance

Journal article in Clinical Pharmacology & Therapeutics, published online on 2026-06-18. Written by Jeanne Petit and 7 co-authors. Institution: Univ Toulouse, Oncopole-Claudius Regaud, IUCT-Oncopole, Inserm, CRCT, Toulouse, France. Major MEDLINE topics: Cytochrome P-450 CYP2D6, Tamoxifen, High-Throughput Nucleotide Sequencing, Antineoplastic Agents, Hormonal. Cited 1 times so far (Crossref); 50 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

CYP2D6 metabolizes about 20% of commonly used drugs, including tamoxifen, a major hormone therapy for breast cancer. Although the relationship between tamoxifen pharmacokinetics and CYP2D6 genotype has been demonstrated, residual variability in drug exposure remains unexplained. Given the high genetic polymorphism of CYP2D6 , including copy number variations and hybrid genes, targeted genotyping may fail to capture rare or complex alleles. To explore this limitation, 68 individuals from a cohort of tamoxifen‐treated patients were selected based on discordance between CYP2D6 genotype determined by a targeted approach and phenotype assessed from pharmacokinetic data, and were analyzed using full‐gene next‐generation sequencing with in‐house panel and bioinformatics pipeline. Full CYP2D6 gene sequencing refined genotypes in 41% of patients, and changed metabolizer status in 19%, mainly by detecting common alleles missed by the initial targeted assay. After removing these sources of discrepancy, sequencing improved diplotype assignment in 23.5% and metabolizer status classification in 7.4% of patients, largely driven by the detection of structural variants, with an additional contribution from the rare nonfunctional CYP2D6 *62 allele, identified in one patient. In addition, several rare variants or variants of uncertain significance (including CYP2D6 *22, *23, *28, p.Ala165Gly. and p.Pro264Thr) were identified and further evaluated using adapted in silico prediction strategies, compared with patients' phenotypes and published in vitro data. Comprehensive CYP2D6 sequencing improved gene profiling accuracy in our preselected cohort, while highlighting the remaining challenges of rare variant interpretation in pharmacogenetics‐guided therapeutic drug monitoring.

Subjects

MeSH terms (MEDLINE)

Cytochrome P-450 CYP2D6TamoxifenHigh-Throughput Nucleotide SequencingAntineoplastic Agents, HormonalBreast NeoplasmsHumansFemalePhenotypeGenotypeMiddle AgedPolymorphism, Genetic

Substances

Cytochrome P-450 CYP2D6TamoxifenAntineoplastic Agents, Hormonal

Authors and institutions

  • Univ Toulouse, Oncopole-Claudius Regaud, IUCT-Oncopole, Inserm, CRCT, Toulouse, France.
  • Bioinformatics Department, Oncopole Claudius Regaud, IUCT-Oncopole, Toulouse, France.

ORCID profiles: Jeanne Petit, Etienne Chatelut, Fabienne Thomas

Cite

APA

Petit, J., Plenecassagnes, J., Brice, A., Dalenc, F., Mallet, L., Chatelut, E., Al Saati, A., & Thomas, F. (2026). Does Next Generation Sequencing ( NGS )‐Based CYP2D6 Sequencing Improve Genotype–Phenotype Concordance in Tamoxifen‐Treated Patients?. Clinical Pharmacology & Therapeutics, 120(3), 731-744. https://doi.org/10.1002/cpt.70360

Vancouver

Petit J, Plenecassagnes J, Brice A, Dalenc F, Mallet L, Chatelut E, et al. Does Next Generation Sequencing ( NGS )‐Based CYP2D6 Sequencing Improve Genotype–Phenotype Concordance in Tamoxifen‐Treated Patients?. Clinical Pharmacology & Therapeutics. 2026;120(3):731-744. doi:10.1002/cpt.70360

BibTeX
@article{Petit2026,
  author = {Petit, Jeanne and Plenecassagnes, Julien and Brice, Aurelie and Dalenc, Florence and Mallet, Ludovic and Chatelut, Etienne and Al Saati, Ayman and Thomas, Fabienne},
  title = {Does Next Generation Sequencing ( NGS )‐Based CYP2D6 Sequencing Improve Genotype–Phenotype Concordance in Tamoxifen‐Treated Patients?},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  volume = {120},
  number = {3},
  pages = {731--744},
  doi = {10.1002/cpt.70360}
}
Start for free →